.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Boehringer Ingelheim
Federal Trade Commission
Cipla
Farmers Insurance
QuintilesIMS
Julphar
Novartis
McKesson

Generated: December 18, 2017

DrugPatentWatch Database Preview

Omega-3-carboxylic acids - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for omega-3-carboxylic acids and what is the scope of omega-3-carboxylic acids patent protection?

Omega-3-carboxylic acids
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Omega-3-carboxylic acids has eighty patent family members in thirty-eight countries.

There is one drug master file entry for omega-3-carboxylic acids.

Summary for omega-3-carboxylic acids

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: omega-3-carboxylic acids

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,729,321Autonomous private key recovery► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: omega-3-carboxylic acids

Country Document Number Estimated Expiration
South Africa9603854► Subscribe
Hungary227282► Subscribe
Portugal1755565► Subscribe
Poland323362► Subscribe
European Patent Office2800563► Subscribe
South Korea101198458► Subscribe
Czech Republic9703607► Subscribe
Japan2012149073► Subscribe
Denmark1755565► Subscribe
Taiwan397683► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Novartis
Baxter
Medtronic
Chinese Patent Office
US Army
Mallinckrodt
Harvard Business School
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot